EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Slideshows|August 4, 2017
3 Suspicious Orofacial Findings
Author(s)Robert P. Blereau, MD
Three men over age 50 years, three different lesions: which would concern you?
Advertisement
Two of these lesions were identified during routine physical exams, one was the presenting symptom. All benign? All malignant? Or some combination. Click through the slides to find out.
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
9 Drugs Approved for Primary Care: Q3 2026
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
4
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
5